Select Language
ROR1
ROR1 Overview
| English Name | Inactive tyrosine-protein kinase transmembrane receptor ROR1 | Approved Drugs | 0 |
| Drugs in Clinical Trials | 19 | Target Synonym | EC 2.7.10.1，Inactive tyrosine-protein kinase transmembrane receptor ROR1，NTRKR1，ROR1，Receptor Tyrosine Kinase Like Orphan Receptor 1，Neurotrophic Tyrosine Kinase， Receptor-Related 1，DJ537F10.1，ROR-1 |
| Highest Development Stage | Phase 3 Clinical | ||
| English Name | Inactive tyrosine-protein kinase transmembrane receptor ROR1 |
| Target Synonym | EC 2.7.10.1，Inactive tyrosine-protein kinase transmembrane receptor ROR1，NTRKR1，ROR1，Receptor Tyrosine Kinase Like Orphan Receptor 1，Neurotrophic Tyrosine Kinase， Receptor-Related 1，DJ537F10.1，ROR-1 |
| Approved Drugs | 0 |
| Drugs in Clinical Trials | 19 |
| Highest Development Stage | Phase 3 Clinical |
ROR1 Product List
- Product Category
Protein (20)Beads (1)Cell (1)
- Product Status
Launched (23)
- Species
Human / Cynomolgus / Rhesus macaque (9)Mouse (4)Rat (1)Human (8)
- Tag
Fc Tag (3)His Tag (11)Fc Tag & Avi Tag (2)Avi Tag (1)His Tag & Avi Tag (2)- (3)Mouse IgG Fc Tag (1)
- Conjugate
Unconjugated (10)Biotin-labeled (5)- (3)FITC Labeled (2)PE Labeled (2)APC Labeled (1)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|---|
HOT RO1-HA2H4 |  Human | HEK293 | APC-Labeled Human ROR1 Protein, His TagStar Staining |  | ||
HOT RO1-HP2E3 | Human | HEK293 | PE-Labeled Human ROR1 Protein, His Tag (Site-specific conjugation) |  |  | |
HOT RO1-H5223 | Human / Cynomolgus / Rhesus macaque | HEK293 | Human / Cynomolgus / Rhesus macaque ROR1 (308-395, Kringle domain) Protein, His Tag (MALS verified) |  |  | |
HOT RO1-H522y | Human / Cynomolgus / Rhesus macaque | HEK293 | Human / Cynomolgus / Rhesus macaque ROR1 Protein, His Tag, low endotoxin (MALS verified) |  | |  |
HOT RO1-H82E6 | Human / Cynomolgus / Rhesus macaque | HEK293 | Biotinylated Human / Cynomolgus / Rhesus macaque ROR1 Protein, His,Avitag™ (MALS verified) |  | | |
CHEK-ATP084 | Human | HEK293 | HEK293/Human ROR1 Stable Cell Line | | ||
MBR-K009 | Human | - | Human ROR1-coupled Magnetic Beads | |||
RO1-H52H3 | Human | HEK293 | Human ROR1 (30-305) Protein, His Tag (MALS verified) |  | | |
RO1-HF253 | Human | HEK293 | FITC-Labeled Human ROR1 Protein, Fc Tag |  | | |
RO1-HF258 | Human | HEK293 | FITC-Labeled Human ROR1 Protein, His Tag |  | | |
Total: 22
- 1
- 2
- 3
ROR1 Background
Tyrosine-protein kinase transmembrane receptor ROR1 is also known as Neurotrophic tyrosine kinase, receptor-related 1 (NTRKR1), which belongs to the protein kinase superfamily or tyr protein kinase family or ROR subfamily. ROR1 contains 1 FZ (frizzled) domain, 1 Ig-like C2-type (immunoglobulin-like) domain, 1 kringle domain, 1 protein kinase domain. ROR1 is expressed at high levels during early embryonic development. The expression levels drop strongly around day 16 and there are only very low levels in adult tissues. Isoform Short is strongly expressed in fetal and adult CNS and in a variety of human cancers, including those originating from CNS or PNS neuroectoderm. ROR1 could interact with casein kinase 1 epsilon (CK1ε) to activate phosphoinositide 3-kinase-mediated AKT phosphorylation and cAMP-response-element-binding protein (CREB), which was associated with enhanced tumor-cell growth.
ROR1 Synonyms
ROR1,NTRKR1
Antibody Project Trading Platform
| Project Name | Project Stage | Molecule Type | Molecule Source | Disease Area | Indication |
|---|---|---|---|---|---|
| ROR1 mAb - 01 | Lead | Monoclonal | Full Human | Hematological Malignancy,AutoImmunity | Solid tumor,Blood tumor |
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Zilovertamab vedotin | VLS-101; MK-2140 | Phase 3 Clinical | Oncternal Therapeutics Inc, University Of California San Diego | Neuroblastoma; Leukemia, Lymphocytic, Chronic, B-Cell; Carcinoma, Non-Small-Cell Lung; Waldenstrom Macroglobulinemia; Lymphoma, T-Cell; Burkitt Lymphoma; Leukemia, Myeloid, Acute; Lymphoma, Mantle-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Breast Neoplasms; Sarcoma, Ewing; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, B-Cell, Marginal Zone; Richter's Syndrome; Lymphoma, Follicular; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Stomach Neoplasms; Ovarian Neoplasms; Lymphoma, B-Cell; Hematologic Neoplasms | Details |
| B-013 | B-013; B013 | Phase 3 Clinical | Shanghai Crosslink Pharmaceutical R & D Co Ltd | Ovarian Neoplasms; Triple Negative Breast Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms | Details |
| Zilovertamab | UC-961 | Phase 2 Clinical | University Of California San Diego, Oncternal Therapeutics Inc | Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Immunoproliferative Disorders; Lymphatic Diseases; Immune System Diseases; Prostatic Neoplasms, Castration-Resistant; Lymphoma, Mantle-Cell; Breast Neoplasms; Lymphoproliferative Disorders; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| Nebratamig | GNC-035 | Phase 2 Clinical | Sichuan Baili Pharmaceutical Co Ltd | Solid tumours; Hematologic Neoplasms; Breast Neoplasms; Lymphoma, Non-Hodgkin; Metastatic breast cancer; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| HG-030 | HG-030 | Phase 1 Clinical | Hitgen Inc | Solid tumours | Details |
| anti-ROR1 CAR T-cell therapy (Fred Hutchinson Cancer Research Center/NCI) | Phase 1 Clinical | National Cancer Institute | Neoplasms | Details | |
| EMB-07 | EMB-07 | Phase 1 Clinical | Shanghai Epimab Biotherapeutics, Inc | Solid tumours; Ovarian Neoplasms; Stomach Neoplasms; Triple Negative Breast Neoplasms; Adenocarcinoma of Lung; Pancreatic Neoplasms; Urinary Bladder Neoplasms; Prostatic Neoplasms; Colorectal Neoplasms; Lymphoma; Uterine Neoplasms | Details |
| PB-004 | PB004; PBA-0405; PB004 PureBIKE; PB-004 | Phase 1 Clinical | Pure Biologics SA | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Sarcoma | Details |
| PRGN-3007 | PRGN-3007 | Phase 1 Clinical | Precigen Inc | Hematologic Neoplasms; Solid tumours; Lymphoma, Large B-Cell, Diffuse; Triple Negative Breast Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| RD-14 | RD-14; RD-14-01; CTE001; RD14-01 | Phase 1 Clinical | Nanjing Bioheng Biotech Co Ltd | Ovarian Neoplasms; Breast Neoplasms; Lymphoma, Non-Hodgkin | Details |
| SYS-6005 | SYS-6005; SYS6005Y; SYS6005 | Phase 1 Clinical | Jushi Biopharmaceutical Co Ltd | Neoplasms | Details |
| HDM-2005 | HDM2005; HDM-2005 | Phase 1 Clinical | Hangzhou Zhongmei Huadong Pharmaceutical Co Ltd | Solid tumours; Hematologic Neoplasms; Neoplasms; Lymphoma | Details |
| ZPC-21 | ZPC-21; IM-1021 | Phase 1 Clinical | Zentalis Pharmaceuticals Inc | Solid tumours; Hematologic Neoplasms; Neoplasms | Details |
| BR-111A | BR-111A; BR111A; BR-111-A | Phase 1 Clinical | BioRay Pharmaceutical Co Ltd | Hematologic Diseases; Solid tumours; Neoplasms | Details |
| NM32-2668 | NM-32-2668 | Phase 1 Clinical | Numab Therapeutics Ag | Leiomyosarcoma; Carcinoma, Renal Cell; Esophageal Neoplasms; Adenocarcinoma of Lung; Carcinoma, Ovarian Epithelial; Triple Negative Breast Neoplasms; Neoplasms; Liposarcoma; Mesothelioma; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Endometrial Neoplasms; Adenocarcinoma; Melanoma | Details |
| LYL-797 | LYL-797 | Phase 1 Clinical | Lyell Immunopharma Inc | Solid tumours; Triple Negative Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| NVG-111 | NVG-111 | Phase 1 Clinical | NovalGen Ltd | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
| LCB-71 | CS-5001; LCB-71; ABL-202; ROR1-pPBD | Phase 1 Clinical | Legochem Biosciences Inc, Abl Bio Inc | Solid tumours; Hematologic Neoplasms; Lymphoma, B-Cell; Lymphoma | Details |
| SIM-201 | SIM-201; SIM-0201 | Phase 1 Clinical | Jiangsu Simcere Pharmaceutical Co Ltd | Solid tumours | Details |
- Overview
- Product List
- Clinical Drug Information
Share to:
Online Message
[North America]: 1 Innovation Way, Newark, DE 19711, USA [Switzerland]: Switzerland Innovation Park Basel Area, Novartis Campus, Lichtstrasse 35, 4056 Basel
Email：order@acrobiosystems.com
Copyright © 2025 ACROBiosystems. All Rights Reserved